NEURO61

Session information

Print

Symposium

[S-16] Symposium 16
Autoimmune epilepsy

Mon. Aug 31, 2020 3:15 PM - 4:45 PM Room 6 (OKAYAMA CONVENTION CENTER 2F Reception Hall)

Chair：AkioIkeda（Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine）,RikiMatsumoto（Division of Neurology, Kobe University Graduate School of Medicine）

[S-16-1] Pathophysiology of autoimmune epilepsy

○Bo Sun1,2, Sarosh Irani1 (1.University of Oxford, UK, 2.Association of British Neurologists, UK)

The epilepsy syndrome of autoimmune etiology, namely, autoimmune epilepsy has attracted attention in recent years. Neural-specific autoantibodies such as anti-NMDA-R and LGI1 antibodies were found, which cause autoimmune epilepsy. Seronegative patients are also existed, and a diagnostic algorithm is required for the diagnosis. Immune therapy should be started in the acute phase as soon as possible in addition to antiepileptic therapy. Especially, new-onset refractory status epilepticus (NORSE) is one of the most challenging status in terms of treatment of acute phase. On the other hand, the presence of smoldering type should be noted with clinical variabilities of autoimmune epilepsy. In this session, pathophysiology, proposal for diagnostic algorithm, management of acute phase, and clinical variabilities of autoimmune epilepsies will be presented by experts in this field.

[S-16-2] Diagnosis of autoimmune epilepsy

○Mitsuhiro Sakamoto1, Riki Matsumoto2, Akio Ikeda3 (1.Department of Neurology, Rakuwakai Otowa Hospital, Japan, 2.Division of Neurology, Kobe University Graduate School of Medicine, Japan, 3.Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Japan)

The epilepsy syndrome of autoimmune etiology, namely, autoimmune epilepsy has attracted attention in recent years. Neural-specific autoantibodies such as anti-NMDA-R and LGI1 antibodies were found, which cause autoimmune epilepsy. Seronegative patients are also existed, and a diagnostic algorithm is required for the diagnosis. Immune therapy should be started in the acute phase as soon as possible in addition to antiepileptic therapy. Especially, new-onset refractory status epilepticus (NORSE) is one of the most challenging status in terms of treatment of acute phase. On the other hand, the presence of smoldering type should be noted with clinical variabilities of autoimmune epilepsy. In this session, pathophysiology, proposal for diagnostic algorithm, management of acute phase, and clinical variabilities of autoimmune epilepsies will be presented by experts in this field.

[S-16-3] Clinical management for an acute phase of autoimmune epilepsy

○Yuto Uchida1,2, Daisuke Kato3, Kiyohito Terada4, Noriyuki Matsukawa1 (1.Nagoya City University, Japan, 2.Toyokawa City Hospital, Japan, 3.Nagoya University, Japan, 4.Yokohama Minoru Epilepsy&Developmental Clinic, Japan)

The epilepsy syndrome of autoimmune etiology, namely, autoimmune epilepsy has attracted attention in recent years. Neural-specific autoantibodies such as anti-NMDA-R and LGI1 antibodies were found, which cause autoimmune epilepsy. Seronegative patients are also existed, and a diagnostic algorithm is required for the diagnosis. Immune therapy should be started in the acute phase as soon as possible in addition to antiepileptic therapy. Especially, new-onset refractory status epilepticus (NORSE) is one of the most challenging status in terms of treatment of acute phase. On the other hand, the presence of smoldering type should be noted with clinical variabilities of autoimmune epilepsy. In this session, pathophysiology, proposal for diagnostic algorithm, management of acute phase, and clinical variabilities of autoimmune epilepsies will be presented by experts in this field.

[S-16-4] Clinical variability of autoimmune epilepsy

○Kazutaka Jin (Department of Epileptology, Tohoku University Graduate School of Medicine, Japan)

The epilepsy syndrome of autoimmune etiology, namely, autoimmune epilepsy has attracted attention in recent years. Neural-specific autoantibodies such as anti-NMDA-R and LGI1 antibodies were found, which cause autoimmune epilepsy. Seronegative patients are also existed, and a diagnostic algorithm is required for the diagnosis. Immune therapy should be started in the acute phase as soon as possible in addition to antiepileptic therapy. Especially, new-onset refractory status epilepticus (NORSE) is one of the most challenging status in terms of treatment of acute phase. On the other hand, the presence of smoldering type should be noted with clinical variabilities of autoimmune epilepsy. In this session, pathophysiology, proposal for diagnostic algorithm, management of acute phase, and clinical variabilities of autoimmune epilepsies will be presented by experts in this field.